Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.

WW International shares are trading higher by 79% during Tuesday's session. The company announced a new partnership with Eli ...

WW International (NASDAQ:WW) stock surges with a new partnership to offer Eli Lilly's (LLY) weight-loss therapy Zepbound.

CVS Health's pharmacy benefits manager said weight-loss drugs from rival drugmaker Novo Nordisk will become the preferred ...

The company cut its adjusted earnings per share guidance for the full year to $22.50 to $24.00, down from its previous ...

Eli Lilly sued Willow Health Services Inc., based ... which treats diabetes, and Zepbound, which treats obesity. Compound medicine providers were allowed to make and distribute copycat versions ...

Eli Lilly and Company LLY will report its first ... diabetes drug Mounjaro and weight loss medicine, Zepbound. Sales of Mounjaro and Zepbound were below expectations in the second half of 2024.